Recent Articles

April 14, 2017 3:00 pm
Rahael Maladwala, Associate Healthcare Analyst, GlobalData
Risperidone was originally marketed as Risperdal by Janssen Pharmaceuticals and is currently available as two formulations.
April 13, 2017 9:41 am
Ryan Bushey
Bristol-Myers Squibb is reducing its portfolio by licensing two experimental assets to other companies.
April 12, 2017 8:00 am
Raymond A. Huml, MS, DVM, RAC and Margaret Dean, MBA, Quintiles MS
Rare disease research was once a neglected aspect of pharmaceutical research, relegated to non-profits and philanthropic projects.
April 11, 2017 9:51 am
Ryan Bushey
The Woburn, Massachusetts-based startup is getting closer to launching a novel drug engineered to treat chronic noise-induced hearing loss.
April 11, 2017 8:59 am
Nathan A. Yee, Ph.D. and Jose M. Mejia Oneto, M.D., Ph.D., Shasqi
Localized adjuvant treatment has proven useful for cancer immunotherapy.
April 7, 2017 3:36 pm
Ryan Bushey
The FDA made the decision based on the results from two open label-clinical trials.
April 7, 2017 9:24 am
Ryan Bushey
The FDA made its decision to give this designation after reviewing data from a Phase 2 study.
April 6, 2017 8:48 am
Sharron Gargosky, Chief Clinical & Regulatory Officer, OncoSec Medical
Immunotherapy and treatments such as checkpoint inhibitors like anti-PD-1 are the mainstay of the anti-cancer arsenal.
April 5, 2017 12:03 pm
Ryan Bushey
The project received $1.8 billion in funding after the passage of the 21st Century Act in December 2016.
April 4, 2017 12:01 pm
Ryan Bushey
Investigators running this randomized, double-blind trial enrolled with 945 patients diagnosed with unresectable stage III or stage IV melanoma.
Subscribe to Drug Discovery & Development